TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult OAB patients who present with OAB symptoms, including micturitions \>= 8 per day and urgency urinary incontinence \>= 1 per day.~Exclusion Criteria:~* Patient has known hypersensitivity to the active substance (fesoterodine fumarate) or to peanut or soya or any of the excipients.~* Patient has a known neurological disease influencing bladder function.~* Patient has a complication of lower urinary tract pathology potentially responsible for urgency or incontinence, clinically relevant bladder outlet obstruction or pelvic organ prolapse.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fesoterodine fumarate 4 mg (Double-Blind) (Type: EXPERIMENTAL): None
- Placebo (Double-Blind) (Type: PLACEBO_COMPARATOR): None
- Fesoterodine fumarate 8 mg (Double-Blind) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects were aged from 16 to 70 years, inclusive. Subjects under 18 years of age were only included where legally permitted and ethically accepted~* Subjects had well-characterized localization-related Epilepsy or generalized Epilepsy according to the International League Against Epilepsy (ILAE) classification~* For subjects suffering from localization-related Epilepsy: subjects had at least 2 Partial-Onset Seizures (POSs) whether or not secondarily generalized per month during the 3 months preceding Visit 1 according to the ILAE classification~* For subjects suffering from localization-related Epilepsy: subjects had at least 4 Partial-Onset Seizures (POSs) whether or not secondarily generalized during the 4-week Baseline Period according to the ILAE classification~* For subjects suffering from generalized Epilepsy: subjects had at least 2 Type II-seizure days per month during the 3 months preceding Visit 1 according to the ILAE classification~* For subjects suffering from generalized Epilepsy: subjects had at least 4 Type II-seizure days during the 4 week Baseline Period according to the ILAE classification~* Subjects were uncontrolled while treated by 1 to 3 permitted concomitant Antiepileptic Drugs (AEDs). Vagal nerve stimulation was allowed and was not counted as a concomitant AED~Exclusion Criteria:~* For subjects who suffered from localization-related Epilepsy: history or presence of Seizures occurring only in clusters (too frequently or indistinctly separated to be reliably counted) before Visit 2 or occurring only as Type IA non-motor~* Subjects with a history or presence of Status Epilepticus during the year preceding Visit 1 or during Baseline

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo tablets administered twice a day
- Brivaracetam (Type: EXPERIMENTAL): A flexible dose of Brivaracetam tablets, administered twice a day, starting with a dose of 20 mg/day and could increase to 50 mg/day, 100 mg/day or 150 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 12 to 15 months of age (not reached their 16th month birthday);~* In good health;~* Parent/guardian available by telephone or for home visits;~* Ability of the parent/guardian to understand and comply with the requirements of the protocol;~* Signed informed consent by parent/guardian; and~* Up to date with the primary series of recommended vaccines per standard clinic practice and local vaccine availability.~Exclusion Criteria:~* Previous known measles, mumps, rubella or varicella disease;~* Previous vaccination against measles, mumps, rubella or varicella disease;~* Hypersensitivity to egg or egg protein;~* Signs or symptoms of any immunosuppressive or immune deficiency disease or ongoing immunosuppressive therapy; or an immunosuppressed individual living in the same household;~* Acute febrile (\>100.0oF \[37.8°C\] oral) illness or clinically significant upper respiratory illness within the 72 hours prior to enrollment;~* Use of aspirin (acetylsalicylic acid) or aspirin-containing products in the month prior to enrollment, or expected use of aspirin while enrolled in this study;~* Administration of any intranasal medication within two weeks prior to enrollment or expected receipt during this study;~* Administration of any live virus vaccine within one month prior to enrollment through 30 days after Visit 3;~* Administration of any inactivated vaccine within two weeks prior to enrollment through 30 days after Visit 3;~* Participation in another investigational trial within one month prior to enrollment or expected enrollment in another investigational trial during this study;~* Receipt of any blood product within three months prior to vaccination or expected receipt within the study duration; and~* Any condition which, in the opinion of the investigator, would interfere with the interpretation or evaluation of the vaccines.~* History of two or more episodes of medically attended wheezing illness by parent/guardian report.~* History of medically attended wheezing illness or bronchodilator medication use within four weeks of enrollment by parent/guardian report.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 15 Months
- Healthy Volunteers: t

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): FluMist
- 3 (Type: PLACEBO_COMPARATOR): Placebo
- 1 (Type: ACTIVE_COMPARATOR): FluMist with other solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Desflurane and Postoperative Sleep Quality in Patients Undergoing Elective Breast Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Undergoing elective breast surgery~2. Age 18-75 years old~3. ASA-PS grade I or II~4. Those who voluntarily participate in the research and sign the informed consent~Exclusion Criteria:~1. Cognitive impairment (MMSE \<27) before the operation~2. The patients received adjuvant chemotherapy before the operation~3. At present, they are taking psychoactive, opioid, anti-anxiety, and hypnotic drugs~4. Known or treated patients with obstructive sleep apnea~5. Patients with other cancers

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Desflurane Inhalation Group (Type: EXPERIMENTAL): Anesthesia maintenance: Desflurane inhalation (MAC 1.0-1.2) Sufentanil 0.3-0.5 μg / (kg·h) Cisatracurium 1-3 μg / (kg·min)
- Propofol Group (Type: ACTIVE_COMPARATOR): Anesthesia maintenance: Propofol TCI: 3-4ug / ml Sufentanil 0.3-0.5 μg / (kg·h) Cisatracurium 1-3 μg / (kg·min)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol.~* A man or woman aged 65 years or older at the time of the vaccination.~* Written informed consent obtained from the subject.~* Subjects with residence status allowing free mixing with general community.~Exclusion Criteria:~* Bedridden subjects~* Previous vaccination against influenza since February 2008.~* Previous vaccination in the last three years with an investigational adjuvanted candidate seasonal or pandemic influenza vaccine.~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Any contra-indication to intramuscular administration of the influenza vaccines.~* History of hypersensitivity to a previous dose of influenza vaccine.~* History of allergy or reactions likely to be exacerbated by any component of the vaccine including egg and chicken protein.~* Acute disease at the time of enrolment. Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. Oral temperature \<37.5°C (99.5°F).

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- FluNG Group (Type: EXPERIMENTAL): subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
- Fluarix Group (Type: ACTIVE_COMPARATOR): subjects received 2 doses (1 dose per season) of Fluarix™ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess the Impact of PrEP to Tenofovir Gel on the Efficacy of Tenofovir-containing ART on Viral Suppression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Previously enrolled in the CAPRISA 004 or CAPRISA 008 study - placebo or active arms~* Able and willing to provide informed consent to be screened for, and to enrol in, the study~* Able and willing to provide adequate locator information for study retention purposes~* Confirmed HIV infection in the CAPRISA 004 or 008 trial~* Agree to adhere to study visits and procedures~Exclusion Criteria:~* Currently on antiretroviral therapy (including PMTCT prophylaxis)~* Has any other condition that, based on the opinion of the Investigator or designee, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tenofovir, lamivudine and efavirenz (Type: EXPERIMENTAL): None
- Zidovudine, lamivudine and efavirenz (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Group 1 (Non Pregnant Women): Healthy females 18-40 years of age inclusive.~* Group 2 (Healthy Pregnant Women): Healthy pregnant women 18-40 yrs of age (between 28-35 weeks gestation)~Exclusion Criteria:~* Group 1 (Non Pregnant Women): Pregnant or nursing; History of severe allergy to previous vaccines; Known HIV positive~* Group 2 (Healthy Pregnant Women): History of severe allergy to previous vaccines; Known HIV positive

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- 1: GBS Trivalent Vaccine with aluminium - 20/20/20 μg (Type: EXPERIMENTAL): Non-pregnant women who received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
- 2: Placebo - Sterile saline (Type: PLACEBO_COMPARATOR): Non-Pregnant Women who received two injection of saline solution.
- 3: GBS Trivalent Vaccine - 0.5/0.5/0.5 µg (Type: EXPERIMENTAL): Pregnant women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
- 4: GBS Trivalent Vaccine - 2.5/2.5/2.5 µg (Type: EXPERIMENTAL): Pregnant Women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
- 5: GBS Trivalent Vaccine - 5/5/5 µg (Type: EXPERIMENTAL): Pregnant women who received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
- 6: Placebo - Sterile saline (Type: PLACEBO_COMPARATOR): Pregnant Women who received one injection of saline solution.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hyperbaric Bupivacaine Versus Hyperbaric Prilocaine 2% for Cesarean Section Under Spinal Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* American Society of Anesthesiologists physical status (ASA) \< III~* Age 18-40 year~* Body Weight \<110 kg~* Height between 160 and 175 cm~* Gestational age\>37 SA~* Elective cesarean delivery~* Singleton pregnancy~* Non complicated pregnancy~* Signed informed consent obtained prior to any study specific assessments and procedures~Exclusion Criteria:~* Twin pregnancy~* History of 2 cesarean section or more~* Diabetes and gestational diabetes~* Placenta praevia~* Congenital foetal abnormality~* Intrauterine growth retardation~* Patient in labour~* Membrane rupture~* Known allergy to local anaesthetics~* Standard contraindications to neuraxial block.~* Disagreement of the patient~* Neurological impairment~* Gestational low blood pressure~* Pre eclampsia and eclampsia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Hyperbaric bupivacaine (Type: PLACEBO_COMPARATOR): Hyperbaric bupivacaine 0.5% will be administered at the dose of 10 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.
- Hyperbaric prilocaine (Type: ACTIVE_COMPARATOR): Hyperbaric prilocaine 2% will be administered at the dose of 50 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participation in study PKU-004 or PKU-006~* Willing and able to provide written, signed informed consent or, in the case of subjects under the age of 18 years, provide written assent (if required) and written informed consent by a parent or legal guardian, after the nature of the study has been explained, and prior to any research-related procedures~* Negative urine pregnancy test at screening (females of child-bearing potential)~* Willing and able to comply with all study procedures~Exclusion Criteria:~* Non-responsive to prior treatment with Phenoptin based on participation in PKU-004 or PKU-006~* Perceived to be unreliable or unavailable for study participation or, if under the age of 18 years, have parents or legal guardians who are perceived to be unreliable or unavailable~* Terminated early from PKU-004 or PKU-006, except for subjects in PKU-004 that rolled into PKU-008 at Week 22, subjects in PKU-006 that rolled into PKU-008 at Week 10, or subjects in PKU-006 that terminated due to elevated Phe levels following dietary Phe increases~* Use of any investigational product other than Phenoptin within 30 days prior to screening, or anticipated requirement for any investigational agent prior to completion of all scheduled study assessments~* Positive urine pregnancy test at screening (non-sterile females of child-bearing potential only), already known to be pregnant or breastfeeding or planning a pregnancy in self or partner during the study~* Female subjects of childbearing potential must be using an effective method of birth control, as determined by the PI, and willing to continue to use acceptable birth control measures~* Concurrent disease or condition that would interfere with study participation or safety (e.g., seizure disorder, oral steroid-dependent asthma or other condition requiring oral or parenteral corticosteroid administration, or insulin-dependent diabetes)~* Any condition that, in the view of the PI, renders the subject at high risk from treatment compliance and/or completing the study~* ALT \> 2 times the upper limit of normal (i.e., Grade 1 or higher based on World Health Organization Toxicity Criteria) at screening (see Appendix 2)~* Serious neuropsychiatric illness (e.g., major depression) not currently under medical control~* Prior history of organ transplantation~* Requirement for concomitant treatment with any drug known to inhibit folate synthesis (e.g., methotrexate)~* Concurrent use of levodopa~* Clinical diagnosis of primary BH4 deficiency

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Metabolism With HDL Cholesterol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 - 65 years~* Free of overt coronary disease~* Body mass index \<35 kg.m-2~* Fasting plasma glucose \> 7 mmol/L-1~* No major illness~Exclusion Criteria:~* Unable to give informed consent~* Smokers~* Abnormal LFT, U\&E, FBE or creatinine

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine for Menopausal Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women age 40 years old or older~* Menopausal symptoms of at least 3 months duration, including irregular periods and/or hot flushes~* Minimum score of 15 on the Hamilton Rating Scale for Depression (17-item),~* Patients will meet criteria for a major depressive episode, verified using the Mini International Neuropsychiatric Interview (MINI).~* Subjects will be able to be treated on an outpatient basis, and~* Subjects will be able to provide written informed consent~Exclusion Criteria:~* Subjects presently taking antidepressant medication,~* Subjects currently using hormone replacement therapy,~* Other Axis I disorders, except Generalized Anxiety Disorder or Panic Disorder, according to the Mini International Neuropsychiatric Interview (MINI)~* uncontrolled narrow angle glaucoma~* known hypersensitivity to duloxetine or any of the inactive ingredients~* treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of randomization or potential need to use an MAOI during the study or within 5 days of discontinuation of study drug.~* Presence of psychotic symptoms,~* History of mania or hypomania,~* HAM-D suicide item score \> 3,~* End stage renal disease or severe renal impairment~* Abnormal uterine bleeding (heavy or prolonged uterine bleeding, menstrual periods occurring more frequently than every 3 weeks, bleeding after sexual intercourse, spotting between periods) that has not been evaluated by a gynecologist.~* Subjects with serious or unstable medical illness, including alcohol or substance abuse, cardiovascular, hepatic, respiratory, endocrine, neuralgic, or hematologic disease, history of seizure disorder~* Subjects taking medications that may interact with duloxetine

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: EXPERIMENTAL): After a one-week placebo lead-in, all eligible subjects will receive Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg Duloxetine per day for 7 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete